Cognitive Effects of Topiramate in Migraine Patients Aged 12 Through 17 Years

Pediatric Neurology

Volumn 42, Issue 3, 2010, Pages 187-195

  Pandina, Gahan J ^a   Ness, Seth ^a   Polverejan, Elena ^a   Yuen, Eric ^a   Eerdekens, Marielle ^b   Bilder, Robert M ^c   Ford, Lisa ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; DIHYDROERGOTAMINE MESILATE; DIPYRONE; ERGOT DERIVATIVE; IBUPROFEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; SUMATRIPTAN; TOPIRAMATE; TRIPTAN DERIVATIVE;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GROUPS BY AGE; HEADACHE; HUMAN; INJURY; INSOMNIA; LEARNING; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MIGRAINE; MIGRAINE WITH AURA; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; PARESTHESIA; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOLOGIC ASSESSMENT; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; RECOGNITION; SIDE EFFECT; SOMNOLENCE; UPPER RESPIRATORY TRACT INFECTION; VISUAL INFORMATION; VOMITING;

ADOLESCENT; ANOREXIA; CHILD; COGNITION DISORDERS; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; MALE; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; REACTION TIME; RECOGNITION (PSYCHOLOGY); SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; SPACE PERCEPTION; VISUAL PERCEPTION;

EID: 76249109358     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2009.10.001     Document Type: Article

References (49)

1. Lewis D., Winner P., Saper J., et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics 123 (2009) 924-934
2. Apostol G., Cady R., Laforet G., et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache 48 (2008) 1012-1025
3. Golden A.S., Haut S.R., and Moshé S.L. Nonepileptic uses of antiepileptic drugs in children and adolescents. Pediatr Neurol 34 (2006) 421-432
4. Ortho-McNeil. Topamax. [package insert] (2005), Ortho-McNeil Neurologics, Titusville, NJ
5. Silberstein S.D., Neto W., Schmitt J., and Jacobs D. MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 61 (2004) 490-495
6. Brandes J.L., Saper J.R., Diamond M., et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 291 (2004) 965-973
7. Diener H.C., Tfelt-Hansen P., Dahlof C., et al. MIGR-003 Study Group. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol 251 (2004) 943-950
8. Silberstein S.D., Lipton R.B., Dodick D.W., et al. Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47 (2007) 170-180
9. Diener H.C., Bussone G., Van Oene J., Lahaye M., Schwalen S., and Goadsby P. TOPMAT-MIG-201 (TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. [Erratum in: Cephalalgia 2007;27:962]. Cephalalgia 27 (2007) 814-823
10. Thompson P.J., Baxendale S.A., Duncan J.S., and Sander J.W. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 69 (2000) 636-641
11. Meador K.J., Loring D.W., Hulihan J.F., Kamin M., and Karim R. CAPSS-027 Study Group. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 60 (2003) 1483-1488
12. Lee H.W., Jung D.K., Suh C.K., Kwon S.H., and Park S.P. Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: a 1-year follow-up. Epilepsy Behav 8 (2006) 736-741
13. Martin R., Kuzniecky R., Ho S., et al. Cognitive effects of topiramate, gabapentin and lamotrigine in healthy young adults. Neurology 52 (1999) 321-327
14. Blum D., Meador K., Biton V., et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 67 (2006) 400-406
15. Gomer B., Wagner K., Frings L., et al. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 10 (2007) 486-494
16. Bourgeois B.F. Determining the effects of antiepileptic drugs on cognitive function in pediatric patients with epilepsy. J Child Neurol 19 Suppl. 1 (2004) S15-S24
17. Aarsen F.K., van den Akker E.L., Drop S.L., and Catsman-Berrevoets C.E. Effect of topiramate on cognition in obese children. Neurology 67 (2006) 1307-1308
18. de Araujo Filho G.M., Pascalicchio T.F., Lin K., Sousa P.S., and Yacubian E.M. Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate. Epilepsy Behav 8 (2006) 606-609
19. Sirén A., Kylliäinen A., Tenhunen M., Hirvonen K., Riita T., and Koivikko M. Beneficial effects of antiepileptic medication on absence seizures and cognitive functioning in children. Epilepsy Behav 11 (2007) 85-91
20. Shorvon S.D. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 37 Suppl. 2 (1996) S18-S22
21. Edwards K.R., and Kamin M. Topiramate TPS-TR Study Group. The beneficial effect of slowing the initial titration rate of topiramate. [Abstract]. Neurology 48 Suppl. 2 (1997) A39
22. Silberstein S.D. Topiramate in migraine prevention. Headache 45 Suppl. 1 (2005) S57-S65
23. De Luca C.R., Wood S.J., Anderson V., et al. Normative data from the CANTAB. I: development of executive function over the lifespan. J Clin Exp Neuropsychol 25 (2003) 242-254
24. Luciana M., and Nelson C.A. The functional emergence of prefrontally-guided working memory systems in four-to- eight year-old children. Neuropsychologia 36 (1998) 273-293
25. Luciana M., and Nelson C.A. Neurodevelopmental assessment of cognitive function using CANTAB: validation and future goals. In: Ernst M., and Rumsey J. (Eds). Coyle J, forward. Functional neuroimaging in child psychiatry (2000), Cambridge University Press, New York 380-392
26. Luciana M., and Nelson C.A. Assessment of neuropsychological function through use of the Cambridge Neuropsychological Testing Automated Battery: performance in 4- to 12-year-old children. Dev Neuropsychol 22 (2002) 595-624
27. Haverkamp F., Hönscheid A., and Müller-Sinik K. Cognitive development in children with migraine and their healthy unaffected siblings. Headache 42 (2002) 776-779
28. Riva D., Aggio F., Vago C., et al. Cognitive and behavioural effects of migraine in childhood and adolescence. Cephalalgia 26 (2006) 596-603
29. Zgorzalewicz M., and Mojs E. Assessment of chosen cognitive functions in children and adolescents with primary headaches. [in Polish]. Przegl Lek 63 Suppl. 1 (2006) 24-28
30. Abu-Arefeh I., and Russell G. Prevalence of headache and migraine in schoolchildren. BMJ 309 (1994) 765-769
31. Salthouse T.A. Implications of within-person variability in cognitive and neuropsychological functioning for the interpretation of change. Neuropsychology 21 (2007) 401-411
32. Tfelt-Hansen P., Block G., Dahlöf C., et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 20 (2000) 765-786
33. Headache Classification Subcommittee; International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 24 Suppl. 1 (2004) 9-160
34. Wasiewski W.W., and Rothner A.D. Pediatric migraine headache diagnosis, evaluation, and management. Neurologist 5 (1999) 122-134
35. Dickstein D.P., Treland J.E., Snow J., et al. Neuropsychological performance in pediatric bipolar disorder. Biol Psychiatry 55 (2004) 32-39
36. Ritchie K., Allard M., Huppert F.A., Nargeot C., Pinek B., and Ledésert B. Computerized cognitive examination of the elderly (ECO): The development of a neuropsychological examination for clinic and population use. Int J Geriatric Psychiatry 8 (1993) 899-914
37. Curran S.L., Andrykowski M.A., and Studts J.L. Short form of the Profile of Mood States (POMS-SF): Psychometric information. Psychol Assess 7 (1995) 80-83
38. Winner P., Rothner A.D., Putnam D.G., and Asgharnejad M. Demographic and migraine characteristics of adolescents with migraine: Glaxo Wellcome clinical trials' database. Headache 43 (2003) 451-457
39. Powers S.W., Patton S.R., Hommel K.A., and Hershey A.D. Quality of life in childhood migraines: clinical impact and comparison to other chronic illnesses. Pediatrics 112 (2003) e1-e5
40. Powers S.W., Patton S.R., Hommel K.A., and Hershey A.D. Quality of life in paediatric migraine: characterization of age-related effects using PedsQL 4.0. Cephalalgia 24 (2004) 120-127
41. Lindman J.P., Lewis L.S., Accortt N., and Wiatrak B.J. Use of the Pediatric Quality of Life Inventory to assess the health-related quality of life in children with recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 114 (2005) 499-503
42. MacDonald R.L., and McLean M.J. Anticonvulsant drugs: mechanisms of action. Adv Neurol 44 (1986) 713-736
43. Rogawski M.A., and Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds. Pharmacol Rev 42 (1990) 223-286
44. White H.S., Brown S.D., Woodhead J.H., Skeen G.A., and Wolf H.H. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41 Suppl. 1 (2000) S17-S20
45. Lowe C., and Rabbitt P. Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge Neuropsychological Test Automated Battery. International Study of Post-Operative Cognitive Dysfunction. Neuropsychologia 36 (1998) 915-923
46. Louis W.J., Mander A.G., Dawson M., O'Callaghan C., and Conway E.L. Use of computerized neuropsychological tests (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly. Cambridge Neuropsychological Test Automated Battery. J Hypertens 17 (1999) 1813-1819
47. Bird C.M., Papadopoulou K., Ricciardelli P., Rossor M.N., and Cipolotti L. Monitoring cognitive changes: psychometric properties of six cognitive tests. Br J Clin Psychol 43 (2004) 197-210
48. Collie A., Maruff P., Darby D.G., and McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 9 (2003) 419-428
49. Luciana M. Practitioner review: computerized assessment of neuropsychological function in children: clinical and research applications of the Cambridge Neuropsychological Testing Automated Battery (CANTAB). J Child Psychol Psychiatry 44 (2003) 649-663